Keros Therapeutics, Inc. Share Price
NASDAQ: KROS | Small CapKeros Therapeutics, Inc. Stock Performance
Open $11.07 | Prev. Close $11.24 | Circuit Range N/A |
Day Range $10.58 - $11.07 | Year Range $9.73 - $22.47 | Volume 26,884 |
Average Traded $10.89 |
Keros Therapeutics, Inc. Share Price Today
As of 29 August 2026, Keros Therapeutics, Inc.'s share price is $11.04. The stock opened at $11.07, compared to its previous close of $11.24. During today's trading session, Keros Therapeutics, Inc.'s share price traded between $10.58 and $11.07, with an average price of $10.82. Over the past 52 weeks, the stock has recorded a high of $22.47 and a low of $9.73. In terms of performance, Keros Therapeutics, Inc.'s share price has declined by 22.32% over the last six months and is down 27.16% on a year-on-year basis.
Keros Therapeutics, Inc. Share Price Chart
Keros Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $410.74M | PE Ratio (TTM) 4.72 | Dividend Yield N/A |
EPS (TTM) $2.34 | Revenue (TTM) $244.06M | Return On Equity (TTM) 28.70% |
Profit Margin 35.65% | Debt to Equity 0.07 | Quarterly Earnings Growth YoY 86.25% |
Keros Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Keros Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment neuromuscular diseases. The company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $10.18 | $11.24 | +11.95% |
Jul 2026 | $10.77 | $10.04 | -5.86% |
Jun 2026 | $11.03 | $10.66 | -5.03% |
May 2026 | $11.20 | $11.23 | +1.08% |
Apr 2026 | $11.49 | $11.11 | +0.54% |
Mar 2026 | $13.95 | $11.05 | -22.21% |
Feb 2026 | $18.28 | $14.21 | -20.55% |
Jan 2026 | $19.57 | $17.88 | -12.07% |
Dec 2025 | $17.50 | $20.34 | +16.20% |
Nov 2025 | $15.07 | $17.50 | +15.13% |
Oct 2025 | $15.90 | $15.20 | -3.92% |
Sep 2025 | $15.56 | $15.82 | +4.42% |
KROS Share Price FAQs
What is Keros Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Keros Therapeutics, Inc. stock?
What is KROS's market capitalisation today?
What is KROS's net income for the last quarter?
What is the 5 year returns of KROS?
What is the high & low stock price of KROS today?
Can I buy KROS shares in India?